Send this resource to your team or professional network.
CJC-1295 and Ipamorelin are GH-axis research peptides that act on different receptors. This guide compares their receptor pathways, explains the CJC-1295 DAC versus No-DAC formats, reviews the peer-reviewed evidence, and separates controlled findings from community anecdotes.
Research Use Only. Not for Human Consumption. Everything below summarises findings reported in the scientific literature and is intended solely for licensed research and laboratory contexts. Nothing here is medical advice, dosing guidance, or a recommendation for human use.
Quick answer: CJC-1295 is a GHRH analogue that increases GH pulse amplitude. Ipamorelin is a GHRP that activates GHS-R1a, a separate pathway involved in pulse initiation. Their distinct targets support different experimental questions and may be evaluated together.
Key Takeaways
- Different targets: CJC-1295 acts at the GHRH receptor, while Ipamorelin acts at GHS-R1a; their distinct targets support complementary research questions.
- CJC-1295 is a GHRH analogue that raises the amplitude of GH pulses; the DAC form is long-acting (reported half-life of days), while the No-DAC form (modified GRF 1-29) is short-acting (~30 minutes).
- Ipamorelin is a pentapeptide GHRP that initiates GH pulses through GHS-R1a. Preclinical studies report less ACTH, cortisol, and prolactin stimulation than with older GHRPs at GH-releasing doses.
- Studies of combined GHRH- and GHRP-pathway stimulation report synergistic GH release, providing the mechanistic rationale for pairing these compound classes.
What Is CJC-1295? (DAC vs No-DAC)
CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH). More precisely, it is a modified form of the biologically active 1-29 fragment of GHRH, known in the literature as GRF(1-29) or a sermorelin-like peptide. GHRH is the hypothalamic signalling molecule that tells the anterior pituitary to synthesise and release growth hormone, so a GHRH analogue is designed to engage that same upstream pathway.
The compound exists in two principal research formats. Their different exposure profiles affect experimental design.
CJC-1295 with DAC (Drug Affinity Complex). The DAC modification adds a maleimidopropionyl group to the lysine residue at position 30. This reactive group forms a bond with circulating serum albumin, which has an extraordinarily long residence time in plasma. By tethering the peptide to albumin, DAC shields it from renal filtration and enzymatic breakdown, dramatically extending its half-life. In a well-cited clinical pharmacokinetic study in healthy adults, the estimated half-life of CJC-1295 was 5.8–8.1 days, with plasma GH increasing 2- to 10-fold for six days or more and IGF-1 remaining elevated for up to 28 days after multiple doses.
CJC-1295 without DAC (No-DAC / Modified GRF 1-29). The No-DAC version omits the albumin-binding complex. It retains the stabilising amino-acid substitutions that protect against rapid degradation, but its action is short and pulsatile, with a half-life reported on the order of roughly 30 minutes. This short-acting profile is why No-DAC CJC-1295 is often favoured in research designs that aim to mimic the body’s natural, pulse-based pattern of GH secretion.
For a deeper treatment of formats, storage, and reconstitution considerations, see the dedicated CJC-1295 DAC vs No-DAC guide.
What Is Ipamorelin?
Ipamorelin is a growth-hormone-releasing peptide (GHRP), a selective pentapeptide (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as an agonist at the growth-hormone secretagogue receptor type 1a (GHS-R1a), the same receptor targeted by the endogenous hormone ghrelin. Where CJC-1295 works through the GHRH receptor, Ipamorelin works through the ghrelin/GHS-R pathway, an entirely separate signalling route into the pituitary.
What distinguishes Ipamorelin from earlier GHRPs such as GHRP-6 and GHRP-2 is its selectivity. In the landmark 1998 paper that first characterised the molecule, Ipamorelin released GH with potency similar to GHRP-6, yet — unlike the other secretagogues tested — it did not release ACTH or cortisol at levels significantly different from GHRH stimulation alone. Later work reported that this clean profile held even at doses far exceeding the effective GH-releasing dose. That selectivity is precisely why Ipamorelin became a preferred tool compound in GH-axis investigations, where cortisol and prolactin confounders complicate interpretation.
The Ipamorelin Canada research guide covers its pharmacology and handling in more detail.
CJC-1295 vs Ipamorelin: Mechanism of Action
CJC-1295 and Ipamorelin activate separate receptors that converge on GH release from anterior-pituitary somatotrophs.
The GHRH pathway (CJC-1295). CJC-1295 binds the GHRH receptor, raises intracellular cAMP, and increases GH pulse amplitude. The DAC form extends exposure through albumin binding, while No-DAC retains a shorter signalling window.
The GHRP/ghrelin pathway (Ipamorelin). By binding GHS-R1a, Ipamorelin raises intracellular calcium through a distinct signalling cascade that helps initiate GH pulses. GHRP-class compounds also suppress somatostatin tone, the inhibitory brake on GH release, further disinhibiting the pituitary.
The pathways converge on the same secretory machinery. Human studies of GHRH plus GHRP administration report potentiated GH release, with peaks larger than either pathway produces alone. Those class-level findings provide a rationale for studying CJC-1295 with Ipamorelin, but they do not establish clinical outcomes or long-term safety for the exact combination.
Side-by-Side Comparison
| Feature | CJC-1295 | Ipamorelin |
|---|---|---|
| Peptide class | GHRH analogue (modified GRF 1-29) | Selective GHRP (pentapeptide) |
| Receptor target | GHRH receptor | GH secretagogue receptor (GHS-R1a / ghrelin receptor) |
| Intracellular signal | Elevates cAMP | Raises intracellular calcium |
| Effect on GH pattern | Increases GH pulse amplitude; DAC form sustains elevated baseline | Initiates GH pulses; suppresses somatostatin tone |
| Reported half-life | DAC: ~5.8–8.1 days (albumin-bound); No-DAC: ~30 minutes | Short-acting, on the order of ~2 hours |
| Cortisol / prolactin impact | No significant prolactin change reported in the cited short-term human study | Preclinical studies report less ACTH, cortisol, and prolactin stimulation than older GHRPs |
| Main research areas | GH/IGF-1 axis signalling, sustained secretagogue models | GH secretagogue selectivity, pulse-initiation models |
| Dual-pathway rationale | Complementary to GHS-R1a agonism in dual-pathway studies | Complementary to GHRH-receptor agonism in dual-pathway studies |
Quick verdict: CJC-1295 models GHRH-receptor signalling and pulse amplitude; Ipamorelin models selective GHS-R1a signalling and pulse initiation. Researchers may study them separately or together depending on the question.
Why Researchers Study CJC-1295 + Ipamorelin Together
Researchers pair a GHRH analogue with a GHRP to stimulate two independent receptors that converge on GH release. Human GHRH-plus-GHRP studies support pathway-level synergy, while direct controlled human evidence for the exact CJC-1295 and Ipamorelin combination remains limited.
CJC-1295 increases pulse amplitude through the GHRH receptor. Ipamorelin activates GHS-R1a and can reduce somatostatin restraint in experimental models. Together, the signals may recruit more of the pituitary’s releasable GH pool than a single-pathway stimulus.
The CJC-1295 format changes the time-course question. DAC-based designs model sustained GHRH-receptor exposure alongside shorter GHS-R1a stimulation. No-DAC designs keep both signals comparatively brief, making them more suitable for experiments focused on discrete pulses. These are experimental distinctions, not dosing recommendations.
For laboratories that prefer a single reconstitution step, the pre-made CJC-1295 + Ipamorelin blend combines both peptides in fixed proportion within one vial. Researchers who prefer to titrate each component independently can instead source them separately: buy Ipamorelin and buy CJC-1295 (No DAC). In all cases, any protocols and ratios reported in the literature should be treated strictly as literature reports, not as guidance for any other use.
Research Applications
Published studies place these pathways in several areas of GH-axis investigation. The following are research contexts described in the literature, not claims of therapeutic benefit.
GH axis and IGF-1 signalling studies. Because the two peptides engage the two principal upstream controls of GH secretion, they are widely used as tool compounds to dissect how amplitude and pulse-initiation signals integrate at the pituitary, and how downstream IGF-1 responses follow.
Body-composition research. Growth hormone and IGF-1 are central regulators of lean-mass and adipose metabolism, and secretagogue models are used in preclinical work exploring these relationships. Findings here are reported at the level of animal models and mechanistic studies.
Recovery and tissue research. The GH/IGF-1 axis is implicated in connective-tissue and recovery-related processes, and secretagogue peptides are studied as means of modulating that axis experimentally.
Sleep-architecture research. Endogenous GH secretion is strongly coupled to slow-wave sleep, and GHRH-pathway signalling in particular has been shown to promote slow-wave sleep — with episodic administration reported as more effective than continuous infusion. This makes GHRH analogues such as CJC-1295 relevant tools in sleep-physiology models.
Across all of these, correct preparation matters for reproducibility. See how to reconstitute peptides for standard laboratory handling of lyophilised material.
Sourcing CJC-1295 and Ipamorelin in Canada
Sourcing is the practical side of any CJC-1295 vs Ipamorelin research plan. For Canadian research operations, sourcing quality and logistics are as important as the science. Anglo Peptides manufactures and ships domestically within Canada, which removes several of the common friction points associated with imported research chemicals.
Made in Canada. Domestic manufacturing means orders are not exposed to international customs holds, seizures, or the extended transit times that often affect peptides shipped across borders. This translates into fast domestic shipping and more predictable delivery for time-sensitive research schedules.
Third-party verified purity. Every batch is independently tested by Janoshik Analytical, a laboratory widely used for peptide purity verification, with results reported at 99%+ purity. A Certificate of Analysis (COA) is provided per batch, so researchers can document the identity and purity of the exact material they receive rather than relying on generic specifications.
Format flexibility. Both peptides are available individually, and the pre-made CJC-1295 + Ipamorelin blend is offered for laboratories that want the studied combination in a single vial with a single reconstitution step. All products are supplied strictly as research-grade material for laboratory use only.
Key Research & Evidence: CJC-1295 vs Ipamorelin
Understanding the evidence behind CJC-1295 vs Ipamorelin means separating two distinct pharmacological classes that act on the growth hormone (GH) axis through different receptors. CJC-1295 is a long-acting analogue of growth-hormone-releasing hormone (GHRH); Ipamorelin is a selective GH secretagogue that mimics ghrelin at the GHS-R1a receptor. This summary is provided strictly for research-use-only (RUO) context. Neither compound is approved by Health Canada for human therapeutic use, and most data below derive from small early-phase clinical studies or preclinical animal models. Nothing here is medical advice or dosing guidance.
CJC-1295 and the GHRH pathway
GHRH binds a Gs-coupled receptor on pituitary somatotrophs, raising intracellular cAMP to drive synthesis and pulsatile release of GH, a system held in check by somatostatin (Mayo 2000). CJC-1295 extends this signal. In the pivotal human study, Teichman 2006 reported that single subcutaneous doses in healthy adults produced dose-dependent increases in mean plasma GH of roughly 2- to 10-fold for six days or more and IGF-I of 1.5- to 3-fold for nine to eleven days, with an estimated half-life of 5.8-8.1 days attributable to the drug-affinity-complex (DAC) technology that binds serum albumin. A key mechanistic question was whether continuous GHRH-receptor stimulation would flatten the natural GH rhythm; Ionescu 2006 found that pulsatile GH secretion persisted during sustained CJC-1295 exposure, raising trough and mean GH while leaving pulse frequency largely intact.
Ipamorelin and the ghrelin/GHRP pathway
The secretagogue arm traces to the discovery that synthetic peptides release GH through a receptor distinct from GHRH. Howard 1996 cloned that receptor (GHS-R), and Kojima 1999 identified its endogenous acylated ligand, ghrelin. Against this backdrop, Raun 1998 characterised Ipamorelin as the first selective GH secretagogue: in rodents it released GH with potency comparable to GHRP-6 but, at equimolar GH-releasing doses, produced no significant rise in ACTH, cortisol or prolactin, whereas GHRP-6 markedly elevated cortisol and ACTH. This selectivity is the central distinction in the CJC-1295 vs Ipamorelin comparison relative to older secretagogues such as GHRP-2 and GHRP-6.
Combination rationale and evidence limits
The rationale for pairing a GHRH analogue with a secretagogue rests on neuroendocrine work showing the two pathways are complementary. Bowers 1990 demonstrated in normal men that a GH-releasing peptide and GHRH together stimulated GH release synergistically rather than additively, implying independent receptor systems that converge at the somatotroph. Secretagogues appear to amplify GH partly by opposing somatostatin tone: Veldhuis 2006 showed ghrelin potentiated GH most strongly with pharmacological somatostatin withdrawal, and Veldhuis 2008 found 24-hour ghrelin infusion augmented pulsatile GH secretion roughly 12-fold. Pombo 1998 indicated GHRP-6’s maximal effect requires endogenous GHRH. Because physiologic GH is coupled to sleep, this research also intersects with sleep neuroendocrinology (Born 1988; Van Cauter 2004).
Several caveats apply across the entire CJC-1295 vs Ipamorelin literature. The human CJC-1295 data come from small ascending-dose studies; much of the Ipamorelin evidence is preclinical; and none of the “stack” claims popularised in fitness contexts have been validated in controlled human trials with meaningful clinical endpoints. Reported responses describe biomarkers (GH, IGF-I) rather than approved outcomes, and long-term human safety is not established. These compounds are supplied for laboratory research only and are not for human consumption.
Safety, Side Effects and Evidence Limitations
The available evidence does not establish the long-term safety or side-effect profile of CJC-1295, Ipamorelin, or their combination. The human CJC-1295 studies were small and short, focused mainly on GH and IGF-I biomarkers; much of the Ipamorelin evidence is preclinical, and controlled human trials of the combined stack with clinically meaningful endpoints are lacking.
Online reports of water retention, sleep changes, or other effects are anecdotal and cannot establish prevalence or causation. Neither compound is approved by Health Canada for human therapeutic use. Qualified laboratories should define safety monitoring and stopping criteria within an approved research protocol; this article does not provide dosing or self-administration guidance.
Frequently Asked Questions
Bottom line: the CJC-1295 vs Ipamorelin choice is rarely strictly either/or. Most CJC-1295 vs Ipamorelin research runs the two peptides together to model a fuller, more physiological GH pulse.
What is the difference between CJC-1295 and Ipamorelin?
They belong to different peptide classes and act on different receptors. CJC-1295 is a GHRH analogue that works through the GHRH receptor to increase the amplitude of GH pulses. Ipamorelin is a selective GHRP that works through the ghrelin/GHS-R receptor to initiate pulses and reduce somatostatin inhibition. Because they target separate pathways, in the CJC-1295 vs Ipamorelin comparison they are complementary rather than interchangeable.
Can or should CJC-1295 and Ipamorelin be combined in research?
Researchers may pair them because GHRH and GHRP pathways are complementary. Direct controlled human evidence for the exact CJC-1295 and Ipamorelin combination is limited, so a qualified researcher should base any combined protocol on the study question, approved methods, and institutional oversight. Literature reports are not guidance for human use.
What is the difference between CJC-1295 DAC and No-DAC?
The DAC (Drug Affinity Complex) version binds circulating albumin, extending its reported half-life to roughly 5.8–8.1 days and sustaining an elevated GH-releasing signal. The No-DAC version (modified GRF 1-29) lacks this complex and is short-acting, with a reported half-life around 30 minutes, giving the pulsatile profile that many researchers pair with a short-acting GHRP such as Ipamorelin.
Does Ipamorelin raise cortisol?
Preclinical studies characterize Ipamorelin as a selective GH secretagogue with less ACTH, cortisol, and prolactin stimulation than older GHRPs at GH-releasing doses. Human evidence remains limited, so this finding should not be treated as a clinical safety claim.
Which is better, CJC-1295 or Ipamorelin?
CJC-1295 models amplitude and baseline GH-releasing tone; Ipamorelin models selective pulse initiation. Neither is universally better: the relevant compound depends on the experimental endpoint, and some studies evaluate both pathways.
What are the downsides and safety limitations of CJC-1295 and Ipamorelin research? The main limitation is the evidence base: human CJC-1295 studies are small and short, much of the Ipamorelin evidence is preclinical, and controlled human trials of the combined stack are lacking. Long-term human safety and a reliable side-effect profile have not been established.
What is the legal status of CJC-1295 and Ipamorelin in Canada for research?
Both peptides are unapproved by Health Canada and are not authorised as therapeutic products or for human consumption. They are supplied strictly as research-grade chemicals for laboratory and research use only. Researchers are responsible for complying with all applicable institutional, provincial, and federal requirements governing research materials.
Closing Disclaimer
All products and information referenced in this article are provided for Research Use Only and are Not for Human Consumption. CJC-1295 and Ipamorelin are not approved by Health Canada as drugs or therapeutic products, and nothing in this guide constitutes medical advice, a treatment recommendation, or dosing guidance. Any doses, ratios, or protocols mentioned reflect findings reported in the scientific literature and are provided solely for informational and educational purposes in a research context. Community discussion summarised above is anecdotal, is paraphrased for neutrality, and does not represent endorsed outcomes. Handling, storage, and use of these materials are the sole responsibility of the qualified researcher.
References
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. pubmed 9849822
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. pubmed 16352683
- Ionescu M, Frohman LA. Pulsatile GH secretion persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab. 2006;91(12):4792-4797. pubmed 17018654
- Bowers CY, Reynolds GA, Durham D, et al. GH-releasing peptide stimulates GH release and acts synergistically with GHRH in normal men. J Clin Endocrinol Metab. 1990;70(4):975-982. pubmed 2108187
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. pubmed 8688086
- Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. pubmed 10604470
- Mayo KE, Miller T, Bhatt B, et al. Regulation of the pituitary somatotroph by GHRH and its receptor. Recent Prog Horm Res. 2000;55:237-266. pubmed 11036940
- Veldhuis JD, Reynolds GA, Iranmanesh A, Bowers CY. 24-hour ghrelin infusion augments pulsatile GH secretion. J Clin Endocrinol Metab. 2008;93(9):3597-3603. pubmed 18593763
- Veldhuis JD, Reynolds GA, Iranmanesh A, Bowers CY. Ghrelin potentiates GH secretion via somatostatin withdrawal. J Clin Endocrinol Metab. 2006;91(6):2441-2446. JCEM
- Pombo M, Barreiro J, Penalva A, et al. GHRP-6 requires endogenous GHRH for maximal GH stimulation. J Clin Endocrinol Metab. 1998;83(6):2140-2144. pubmed 9543138
- Born J, Muth S, Fehm HL. Sleep onset and slow wave sleep in nocturnal GH and cortisol release. Psychoneuroendocrinology. 1988;13(3):233-243. pubmed 3406323
- Van Cauter E, Latta F, Nedeltcheva A, et al. Reciprocal interactions between the GH axis and sleep. Growth Horm IGF Res. 2004;14(Suppl A):S10-S17. pubmed 15135771
